Not all genetic tests are created equal, and the difference is not just price or brand. The right test depends on the question being asked: confirming a known family mutation, hunting for an unknown cause of a complex condition, or exploring drug-response variants. According to The Jackson Laboratory's clinical education resources, tests range from narrowly targeted analyses to whole-genome sequencing, each detecting different variant types. Meanwhile, the National Human Genome Research Institute distinguishes two very different access pathways—direct-to-consumer and provider-mediated—that determine who orders the test, what oversight exists, and whether results can guide medical decisions.

Understanding Genetic Testing Technologies

Genetic tests differ primarily in analytical scope: how much of the genome they examine and which kinds of variation they can detect. The Jackson Laboratory's comparison of clinical tests lays out a clear hierarchy. Targeted mutation analysis interrogates specific known variants or a limited set of genes, and despite its narrow focus it can detect a wide range of variant classes within those regions—single nucleotide variants (SNVs), insertions and deletions (indels), copy number variants (CNVs), trinucleotide repeats (TNRs), methylation changes, and mitochondrial DNA. Condition-specific panels share this broad detection capability while covering the genes linked to a particular disorder.

Broad multi-gene tests, by contrast, cast a wider net but detect fewer variant classes—typically SNVs and indels only, according to the same comparison. Exome sequencing reads all protein-coding regions, which represent roughly 1–2% of the genome yet contain most known disease-causing variants; it also primarily detects SNVs and indels, meaning it may miss variants in non-coding regions or large structural rearrangements. Genome sequencing covers coding and non-coding regions alike and adds mitochondrial DNA to the SNV and indel detection shared by exome testing, providing the most comprehensive view of an individual's genetic makeup.

A narrative review of genomic medicine published in 2025 situates these technologies historically: next-generation sequencing—including whole-genome, whole-exome, whole mitochondrial, targeted exome, and RNA sequencing—has countered the limitations of older methods like Sanger sequencing, karyotyping, and chromosomal arrays for rare genetic diseases. The scale of exome sequencing is illustrated by the UK Biobank, where whole-exome sequencing of roughly 500,000 individuals identified about 564 distinct genes with significant trait associations, from CHD2 in B-cell chronic lymphocytic leukemia to COL1A1 in bone disorders and SERPINC1 in coagulation defects. The Jackson Laboratory notes a general principle: as a test's scope increases, its diagnostic yield also increases.

Genetic Testing Technologies: A Comparison for Personalized Medicine

The table below consolidates the technical specifications from The Jackson Laboratory's clinical comparison, matching each technology to its analytical scope and the variant types it is designed to detect. Use it to connect a specific clinical need—confirming a known family variant versus searching for an unknown cause of a complex condition—to the appropriate technology.

Comparison of major genetic testing technologies for personalized medicine
Test TypeWhat It AnalyzesTypical Use CaseTypes of Variants Detected
Targeted mutation analysisSpecific known variants or a limited set of genesConfirming a suspected mutation, such as a known family variantSNVs, indels, CNVs, TNRs, methylation changes, and mtDNA within the targeted regions
Condition-specific panelGenes linked to a particular disorderEvaluating a defined clinical conditionSNVs, indels, CNVs, TNRs, methylation changes, and mtDNA within the panel's genes
Broad multi-gene testA larger set of genes across conditionsScreening many genes when the causative gene is uncertainSNVs and indels
Exome sequencingAll protein-coding regions (roughly 1–2% of the genome, where most known disease-causing variants lie)Searching for an unknown cause of a suspected genetic conditionSNVs and indels; may miss non-coding variants and large structural rearrangements
Genome sequencingThe entire genome, coding and non-coding regionsThe most comprehensive search when other tests have not yielded answersSNVs, indels, and mtDNA across the whole genome—the most complete detection of genetic variation

Two caveats keep this comparison honest. First, broader scope trades depth of variant-type coverage for breadth: a broad multi-gene test or exome sequence detects fewer variant classes than a well-designed targeted analysis, even though it examines far more DNA. Second, the Jackson Laboratory comparison also lists chromosomal microarray analysis (CMA), which detects indels and CNVs—but only deletions and duplications larger than roughly 100 kilobases, with the exact threshold depending on the specific CMA methodology used.

Direct-to-Consumer vs. Provider-Mediated Genetic Testing

Technology is only half the picture; the other half is how a test reaches you. The National Human Genome Research Institute's guidance for healthcare professionals draws a sharp line between direct-to-consumer genetic testing (DTC-GT) and provider-mediated genetic testing (PM-GT). In DTC-GT, consumers purchase tests marketed directly to them, often for insights into ancestry, wellness traits, or predispositions to certain conditions, without direct healthcare professional involvement. In PM-GT, a healthcare professional engages in the testing process—though the institute notes that this involvement may be limited to placing or approving the test order with minimal discussion, and the professional may be employed by the testing company and may not know the consumer at all.

The differences in oversight matter. According to the institute's FAQ, DTC-GT is often completed without traditional genetic counseling, risk assessment, or informed consent confirming that the consumer understands the implications of possible results. The results can be overwhelming, non-actionable, or distressing without the support of a qualified professional—and ancestry findings can reveal unexpected, potentially distressing genetic relationships to biological relatives. These are not abstract concerns; they describe the actual experience of consumers navigating results alone.

The Critical Step of Clinical Confirmation

Here is the detail that most consumer-facing marketing leaves out: a DTC result suggesting a health risk is, by itself, generally not enough to guide medical care. The National Human Genome Research Institute is explicit about pharmacogenomic testing in particular. At the time of its writing, FDA-approved DTC pharmacogenomic tests were limited to eight genes and 33 total variants that may impact drug response. Those results may inform a decision to pursue additional testing—but the majority of DTC pharmacogenomic tests are not approved to be used directly to change prescribing, and confirmatory clinical testing is needed.

In practice, that means a clinician who receives a patient's DTC result indicating a health risk will order a new test from a CLIA-certified laboratory to validate the specific finding before it can inform medical decisions. The institute also advises healthcare professionals to counsel patients not to use DTC pharmacogenomic results to modify or discontinue their medication regimen on their own. The consumer test, in other words, can be a starting point for a clinical conversation—but the clinical-grade test is what carries medical weight.

Making Informed Decisions in Genetic Testing

When considering genetic testing for personalized medicine, individuals and healthcare professionals should carefully evaluate the specific clinical question, the analytical scope of the test, and the access model (DTC vs. provider-mediated) to ensure appropriate and clinically actionable results. The evidence supports a simple framework: match the question to the technology, and match the decision to the delivery model. A known family variant points toward targeted analysis; an undiagnosed complex condition points toward exome or genome sequencing, with the trade-off that broader tests detect fewer variant classes while covering far more DNA.

The delivery model determines what happens after results arrive. DTC tests can offer preliminary insights without counseling, risk assessment, or informed consent, and their pharmacogenomic results are not approved to directly change prescribing. The measurable indicator of a well-navigated testing journey is concrete: a healthcare provider orders a confirmatory genetic test from a CLIA-certified laboratory following a direct-to-consumer test result indicating a health risk. That confirmatory step—not the consumer report itself—is what converts raw genetic data into clinically actionable information.

Sources